US HHS takes additional steps toward development of vaccine for swine flu

27 May 2009

The US Secretary of Health and Human Services, Kathleen Sebelius, has announced that the Department will take important steps necessary to  prepare for potential commercial-scale production of a candidate vaccine  for the novel influenza A ( H1N1; Marketletters passim). The Secretary  is directing approximately $1.0 billion in existing funds that will be  used for clinical studies that will take place over the summer and for  commercial-scale production of two potential vaccine ingredients for  the pre-pandemic influenza stockpile.

Ms Sebelius said: "preparation and planning are critical to keep  Americans safe in the face of a potential pandemic." She added: "our  goal throughout this new H1N1 outbreak has been to stay one step ahead  of the virus. An important part of this effort has been our work to  develop a potential vaccine because vaccines can help prevent and  control influenza virus outbreaks."

New orders placed via existing flu vaccine contracts

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight